LAG3 and melanoma: For example, the LAG-3 inhibitor relatlimab combined with nivolumab is U.S. Food and Drug Administration (FDA)-approved for melanoma, while TIGIT and TIM-3 inhibitors are primarily being evaluated in combination with PD-1 inhibitors (152–154).